Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
TEL AVIV, Israel, April 06, 2017 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its previously announced underwritten public offering of the Company’s securities due to adverse market conditions. H.C. Wainwright had been serving as the underwriters for the proposed offering. The offering was conducted pursuant to a registration statement Form F-1 filed with the U.S. Securities and Exchange Commission.
The Company will provide a business update in the near future that deals with its financing plans and clinical development program for patients with Ocular Pharyngeal Muscular Dystrophy (OPMD) using its investigational proprietary intravenous (IV) form of trehalose 90 mg/mL solution.
About Bioblast Pharma Ltd.
Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Bioblast is traded on the NASDAQ under the symbol “ORPN.” For more information, please visit our website: www.BioblastPharma.com, the content of which is not incorporated herein by reference.
INVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC [email protected] Phone: 212-915-0685
